Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04589182
Other study ID # PDSL-EDS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 20, 2020
Est. completion date October 31, 2022

Study information

Verified date June 2021
Source University of Zurich
Contact Simon Schreiner, MD
Phone +41 44 355 55 11
Email simon.schreiner@usz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a randomized, double-blind, sham-controlled cross-over trial to assess the efficacy as well as safety and tolerability of auditory SWS enhancement on measured outcomes in Parkinson disease (PD) patients with disturbed nighttime sleep. Additionally, the investigators will assess the feasibility and efficacy of auditory slow-wave sleep (SWS) enhancement in Mild Cognitive Impairment (MCI) and Huntington Disease (HD) patients in a pilot study.


Description:

The study is a randomized, double-blind, sham-controlled cross-over trial to assess the efficacy as well as safety and tolerability of auditory SWS enhancement on measured outcomes in PD patients with disturbed nighttime sleep. Patients will be randomized to 2 groups: Group 1 will first be treated with auditory stimulation for 3 nights and then - after a wash-out period of 4 nights - switched to 3 nights of sham stimulation. Group 2 will first receive sham-stimulation for 3 nights and then switch to 3 nights of auditory stimulation treatment. The wash-out period in between will be 4 nights. Patients and investigators assessing the outcomes will be blinded to the conditions. All interventions will take place at the patients' homes. The pilot study is aimed at assessment of safety, tolerability, feasibility and efficacy of auditory SWS enhancement on measured outcomes in MCI and HD patients with disturbed nighttime sleep. Patients will be treated with verum or sham auditory stimulation for 2 consecutive nights. All interventions will take place at the patients' homes.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date October 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent as documented by signature - Diagnosis of PD along international criteria with mild to moderate disease severity (Hoehn- Yahr (HY) stages ll-lll), - Self-reported sleep problems and subjectively impaired sleep quality (PDSS-2 sleep quality subscale (items 1-3 and 14) =7) - Stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study - Ability to apply the intervention for the duration of study, either alone or with help of co-habitant - Sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes - Dosing of dopaminergic and other PD treatment must have been stable for at least 14 days prior to the first intervention period - Negative pregnancy test during screening (except in women who are surgically sterilized/hysterectomized or post-menopausal for longer than 1 year), - Age above 18 years Exclusion Criteria: - Known presence of neurologic (other than PD), psychiatric, or sleep disorders (others than associated with PD) - Parkinsonism without response to levodopa; Atypical Parkinsonian syndromes - Severe medical conditions as renal insufficiency, liver failure or congestive heart failure - The regular use of benzodiazepines and other central nervous system (CNS)-depressant substances, as well as melatonin and other sleep inducing substances - Inability to hear the tones produced by the MHSL-SleepBand device - Absence of slow-wave enhancement by auditory stimulation during the screening night - Skin disorders/problems/allergies in face/ear area that could worsen with electrode application - Failure to give informed consent - Known or suspected drug- or medication abuse - Known or suspected non-compliance - Inability to follow the procedures of the study, e.g. due to language problems, cognitive deficits - Cognitive impairment (Montreal Cognitive Assessment - MoCA <24) - Participation in another study with investigational drug within the 30 days preceding and during the present study - Previous enrolment in the current study - Enrolment of the investigator, his/her family members, employees and other dependent persons - Shift work (work during the night) - Travelling more than 2 time zones in the last month before intervention starts or during intervention (start of intervention will be adapted to fit with this criteria) - Substance or alcohol abuse (i.e. > 0.5 l wine or 1 l beer per day) - High caffeine consumption (> 5 servings/day; including coffee, energy drink) - Planned medical intervention of substantial relevance, e.g. surgery, during intervention (routine assessments, e.g. check-ups will be allowed) - Women who are pregnant or breast feeding, - Intention to become pregnant during the course of the study, - Lack of safe contraception, defined as: Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female patients who are surgically sterilized/hysterectomized or postmenopausal for longer than 1 year are not considered as being of child bearing potential. Pilot studies: Inclusion criteria: - Informed Consent as documented by signature (see Informed Consent Form), - Age above 18 years - The diagnosis of MCI along international criteria or manifest HD (diagnosis of HD confirmed by genetic testing, patients above the age of 18 years, manifest HD, diagnostic confidence of 4) - Stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study, - Stable regimen of therapeutic drugs for at least 2 weeks prior to the intervention, - For HD patients: self-ambulatory - Native German speaker or good understanding of German. Translation assistance will be accepted, if this will allow a nonnative German speaker to comprehensively follow the study protocol including all questionnaires - Ability to apply the intervention for the duration of study, either alone or with help of co-habitant. Exclusion criteria: - MCI: Present diagnosis of neurologic (other than MCI), interfering psychiatric, or severe internal disease - HD: Diagnosis of juvenile onset HD - HD: History of co-morbid neurological conditions (e.g. multiple sclerosis or stroke), interfering psychiatric or cognitive disorders - Severe medical conditions, such as renal insufficiency, liver failure or congestive heart failure - Inability to hear the tones to be applied during sleep when awake - Skin disorders/problems/allergies in face/ear area that could worsen with electrode application - MCI: absence of a cohabitant who could assist with study applications and procedures - Failure to give informed consent - Known or suspected drug- or medication abuse - Inability to follow the procedures of the study, e.g. due to language problems, cognitive deficits, - Participation in another study with investigational drug within the 30 days preceding and during the present study - Enrolment of the investigator, his/her family members, employees and other dependent persons - substance or alcohol abuse (i.e. > 0.5 l wine or 1 l beer per day), - Planned medical intervention of substantial relevance, e.g. surgery, during intervention (routine assessments, e.g. check-ups will be allowed) - Women who are pregnant or breast feeding, - Intention to become pregnant during the course of the study, - Lack of safe contraception, defined as: Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female patients who are surgically sterilized/hysterectomized or post-menopausal for longer than 1 year are not considered as being of child bearing potential.

Study Design


Intervention

Device:
MHSL- SleepBand
The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
Sham
Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.

Locations

Country Name City State
Switzerland University Hospital Zurich, Neurology department Zürich Zurich

Sponsors (2)

Lead Sponsor Collaborator
Christian Baumann ETH Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subjective sleep quality Changes in subjective sleep quality measured with adapted version of Parkinson Disease Sleep Scale (PDSS2), questions on a scale of 0-4, with 0 indicating better sleep assessed before and after each intervention (day 1 and 4, day 7 and 10)
Primary Pilot study: feasibility of acoustic SWS enhancement Feasibility of acoustic SWS enhancement in MCI and HD patients (enhancement of slow-waves measured with EEG) assessed after intervention (day 10)
Secondary Vigilance Changes in vigilance measured using Psychomotor Vigilance Test (PVT) assessed before and after each intervention (day 1 and 4, day 7 and 10)
Secondary Sleep benefit on motor performance Changes in motor performance assessed with focus motor assessment assessed before and after each intervention (day 1 and 4, day 7 and 10)
Secondary Momentary sleepiness Changes in momentary sleepiness assessed with Karolinska Sleepiness Scale (KSS) on a scale 1-10, with 1 indicating extreme alertness and 10 indicating extreme sleepiness assessed before and after each intervention, and every morning and evening during the intervention (day 1 until 4, day 7 until 10)
Secondary Average sleepiness Average sleepiness throughout the day measured with VAS on a scale 0-100, with 100 indicating extreme sleepiness assessed every evening during the intervention (day 1 until 4, day 7 until 10)
Secondary Mood Changes in mood assessed with Visual Analog Scale (VAS) on a scale 0-100, with 100 indicating extremely good mood assessed every evening during the intervention (day 1 until 4, day 7 until 10)
Secondary Restorative effect of sleep Changes in restorative effect of sleep using VAS, on a scale 0-100, with 100 indicating very refreshing sleep assessed every morning during the intervention (day 1 until 4, day 7 until 10)
Secondary Slow wave enhancement Enhancement of slow waves with auditory stimulation, measured with EEG assessed every night of the intervention (day 1 until 4, day 7 until 10)
Secondary Auditory stimulation algorithm performance Performance of algorithm detecting and stimulating slow waves, measured with EEG assessed every night of the intervention (day 1 until 4, day 7 until 10)
Secondary Pilot study: changes in mood changes in mood assessed on VAS (Visual Analog Scale) on a scale 0-100, with 100 indicating extremely good mood before and after intervention (day 1 and 4, day 7 and 10)
Secondary Pilot study: changes in sleep quality changes in sleep quality assessed on VAS (Visual Analog Scale) on a scale 0-100, with 100 indicating extremely good sleep quality before and after intervention (day 1 and 4, day 7 and 10)
Secondary Pilot study: changes in sleepiness changes in sleepiness assessed on VAS (Visual Analog Scale) on a scale 0-100, with 100 indicating extreme sleepiness before and after intervention (day 1 and 4, day 7 and 10)
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A